Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244816 · ClinicalTrials.gov registry record · Phase 2
Taxoprexin® Treatment for Advanced Eye Melanoma
A Phase 2 study, sponsored by American Regent.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00244816 is a Phase 2 study that has completed, run by American Regent. The registered enrollment target is 22 participants.
The verdict
NCT00244816, a Phase 2 study, has completed, sponsored by American Regent.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with metastatic choroidal melanoma being treated with weekly Taxoprexin® Injection.
Interventions
- DRUG Taxoprexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2005-10 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244816
The ClinicalTrials.gov registry entry for NCT00244816 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American Regent, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Taxoprexin is the first listed.
NCT00244816 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244816 about?
NCT00244816 is a clinical study titled "Taxoprexin® Treatment for Advanced Eye Melanoma". To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failu...
What is the current status of trial NCT00244816?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2005-10. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00244816?
The interventions under investigation include: Taxoprexin (DRUG).
Who is sponsoring clinical trial NCT00244816?
This trial is sponsored by American Regent, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.